Journal article

Prolactin Determinants in Healthy Women: A Large Cross-Sectional Study within the EPIC Cohort

Kaja Tikk, Disorn Sookthai, Theron Johnson, Laure Dossus, Francoise Clavel-Chapelon, Anne Tjonneland, Anja Olsen, Kim Overvad, Laura Baglietto, Sabina Rinaldi, Isabelle Romieu, Heiner Boeing, Antonia Trichopoulou, Pagona Lagiou, Dimitrios Trichopoulos, Giovanna Masala, Claudia Agnoli, Rosario Tumino, Carlotta Sacerdote, Amalia Mattiello Show all

Cancer Epidemiology Biomarkers & Prevention | AMER ASSOC CANCER RESEARCH | Published : 2014


BACKGROUND: Experimental and epidemiologic data suggest that higher circulating prolactin is associated with breast cancer risk; however, how various risk factors for breast cancer influence prolactin levels in healthy women is not clear. METHODS: We analyzed cross-sectional associations between several suggested reproductive and lifestyle risk factors for breast cancer and circulating prolactin among pre- and postmenopausal women, taking into account the use of current postmenopausal hormone therapy, among 2,560 controls from a breast cancer nested case-control study within the EPIC cohort. RESULTS: Adjusted geometric mean prolactin levels were significantly higher among premenopausal women..

View full abstract


Awarded by ERC-AdG (Norway)

Awarded by Spanish Ministry of Health (ISCIII RETICC) (Spain)

Awarded by ISCIII RETIC (Spain)

Awarded by Regional Government of Murcia (Spain)

Awarded by Cancer Research UK

Awarded by Medical Research Council

Awarded by National Institute for Health Research

Funding Acknowledgements

The coordination of EPIC is financially supported by the European Commission (DG-SANCO) and the International Agency for Research on Cancer. The national cohorts are supported by Danish Cancer Society (Denmark); Ligue contre le Cancer, Mutuelle Generale de l'Education Nationale, Institut National de la Sante et de la Recherche Medicale (France); Deutsche Krebshilfe, Deutsches Krebsforschungszentrum and Federal Ministry of Education and Research (Germany); the Hellenic Health Foundation (Greece); Italian Association for Research on Cancer (AIRC) and National Research Council (Italy); Dutch Ministry of Public Health, Welfare, and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onde-rzoek Nederland), World Cancer Research Fund (WCRF), Statistics Netherlands (The Netherlands); Norwegian Research Council, Norwegian Cancer Society, ERC-2009-AdG 232997 and Nordforsk, Nordic Centre of Excellence Programme on Food, Nutrition, and Health (Norway); Health Research Fund (FIS), The Spanish Ministry of Health (ISCIII RETICC RD06/0020/0091) and the Catalan Institute of Oncology, Regional Governments of Andalucia, Asturias, Basque Country, Murcia (no 6236) and Navarra, ISCIII RETIC (RD06/0020; Spain); Swedish Cancer Society, Swedish Scientific Council and Regional Government of Skane and Veasterbotten (Sweden); and Cancer Research UK, Medical Research Council (United Kingdom).